A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Launched by TELIOS PHARMA, INC. · Nov 29, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new eye drop medication called TL-925 to see if it can help people with allergic conjunctivitis, which is an eye condition that causes redness, itching, and discomfort due to allergies. The trial will include about 70 participants who will be randomly assigned to receive either TL-925 or a placebo (a harmless solution with no active ingredients) in both eyes. The purpose is to find out if TL-925 is effective in treating this condition.

To participate, individuals must be 18 years or older and have a documented history of eye allergies. They also need to test positive for certain allergens, like pollen or pet dander, and have good vision. Participants will undergo a screening process and will be monitored while using the eye drops. It's important to note that people with certain eye or health conditions, recent eye surgeries, or infections will not be eligible for this study. The trial is currently recruiting participants, and those who join can contribute to important research that may lead to better treatment options for allergic conjunctivitis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals aged 18 years or older
• • Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.
• • Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.
• • Calculated best-corrected visual activity of 0.7 LogMAR or better
• • Positive bilateral CAC reaction
• Exclusion Criteria:
• • Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study.
• • Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months
• • Any ongoing ocular infection (bacterial, viral or fungal)